Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company

Eli Lilly Appoints Thomas J. Fuchs as First Chief AI Officer to Lead AI Initiatives

Fineline Cube Oct 10, 2024

Eli Lilly and Company (NYSE: LLY) has announced the appointment of Thomas J. Fuchs, Dr.sc.,...

Company Deals

Zephyrm Bioscience Limited Files for IPO on Hong Kong Stock Exchange

Fineline Cube Oct 9, 2024

China-based Zephyrm Bioscience Limited, a biopharmaceutical company specializing in the development of novel pluripotent stem...

Company Drug

Pfizer Halts Development of Sisunatovir, an RSV Antiviral, After Phase II/III Trials

Fineline Cube Oct 9, 2024

U.S. pharmaceutical giant Pfizer (NYSE: PFE) has decided to discontinue the development of sisunatovir, an...

Company Drug

Biogen’s China Unit Gets Conditional NMPA Nod for Qalsody (Tofersen) in ALS Treatment

Fineline Cube Oct 9, 2024

Biogen (NASDAQ: BIIB)’s Chinese subsidiary has announced that it has received conditional approval from the...

Company Drug

Joincare Pharmaceutical Secures NMPA Approval for Triptorelin Microspheres to Treat Endometriosis

Fineline Cube Oct 9, 2024

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced that it has received...

Company Drug

CSPC Pharmaceutical Secures NMPA Approval for Omalizumab Biosimilar

Fineline Cube Oct 9, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received marketing approval...

Company Deals

Ningbo Menovo Pharmaceutical Partners with Nanjing Huawe Medicine for High-End Product Development

Fineline Cube Oct 9, 2024

Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has entered into a strategic partnership with Nanjing...

Company Drug

CSPC Pharmaceutical’s ADC CPO301 Earns Second Fast-Track Designation in the US for NSCLC Treatment

Fineline Cube Oct 9, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its best-in-class antibody drug conjugate...

Company Deals Drug

Bio-Thera Solutions Ltd Strikes Licensing Deal with Gedeon Richter for BAT1706 Biosimilar

Fineline Cube Oct 9, 2024

Guangzhou-based Bio-Thera Solutions Ltd has announced a licensing agreement with Hungary’s Gedeon Richter Plc for...

Company Drug

Jiangsu Aidea Pharmaceutical Secures NMPA Approval for Expanded Indication of Fubangde in HIV Treatment

Fineline Cube Oct 9, 2024

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that the National Medical Products...

Company Drug

Ascentage Pharma Receives Approval for Two Phase III Trials of APG-2449 in NSCLC

Fineline Cube Oct 9, 2024

China-based biopharmaceutical company Ascentage Pharma (HKG: 6855) has announced that it has received approval from...

Company Medical Device

MicroPort Endovascular MedTech’s Fiber Wool Plug Spring Coil Gains NMPA Marketing Approval

Fineline Cube Oct 9, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has received marketing approval from the National...

Policy / Regulatory

NMPA Expands Generic Quality Consistency Evaluation with 83rd Batch of Reference Drugs

Fineline Cube Oct 9, 2024

The National Medical Products Administration (NMPA) in China has announced the release of the 83rd...

Company Deals

Kailera Therapeutics Emerges with USD 400 Million in Series A Funding for Anti-Obesity Pipeline

Fineline Cube Oct 8, 2024

Kailera Therapeutics, a newly launched US-based biotechnology company, secured USD 400 million in Series A...

Company Deals

AstraZeneca Strikes Exclusive Licensing Deal with CSPC Pharma for Oral Lp(a) Disruptor

Fineline Cube Oct 8, 2024

UK pharmaceutical giant AstraZeneca (NASDAQ: AZN, LON: AZN) has announced the signing of an exclusive...

Company Deals

Innovent Biologics and ASK Pharma Forge Strategic Partnership for Limertinib in Lung Cancer Treatment

Fineline Cube Oct 8, 2024

China-based Innovent Biologics Inc. (HKG: 1801) and Jiangsu Aosaikang Pharmaceutical Co., Ltd (ASK Pharma, SHE:...

Company Deals

MediLink Therapeutics Partners with Amgen for Clinical Trial in Small Cell Lung Cancer

Fineline Cube Oct 8, 2024

Suzhou-based biotech MediLink Therapeutics (Suzhou) Co., Ltd has announced a partnership with US pharmaceutical giant...

Company

Cassava Sciences to Pay Over USD 40 Million to Settle SEC Charges Over Alzheimer’s Drug Claims

Fineline Cube Oct 8, 2024

The US Securities and Exchange Commission (SEC) has announced that US-based biotech firm Cassava Sciences...

Company Deals

Wuhan YZY Biopharma Grants Rights to CD3/EpCAM Antibody M701 to Chi Ta TianQing Pharma in China

Fineline Cube Oct 8, 2024

Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced that it has granted Chi Ta...

Company Deals

Regor Therapeutics Strikes Deal with Genentech for CDK Inhibitors, Fetching USD 850 Million Upfront

Fineline Cube Oct 8, 2024

Regor Therapeutics Group, a US-based biotech with significant ties to China, has entered into a...

Posts pagination

1 … 225 226 227 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.